SLC5A2 and fatty liver disease: SGLT2 inhibitors promote hepatoprotection through Akkermansia-enriched remodeling, while thiazolidinediones and DPP-4 inhibitors have neutral or harmful effects on hepatic steatosis (Zhang S. et al., 2024).